What Did the Research Discover?
Researchers studied sacituzumab govitecan (SG) as a possible treatment for advanced endometrial cancer (EC) in patients who had already undergone chemotherapy and immunotherapy. The study was part of the TROPiCS-03 trial, which included patients with various metastatic solid tumors.
In this phase II study, 41 patients with advanced EC received SG in a 21-day treatment cycle. The main goal was to measure how well the treatment worked by assessing tumor response and disease progression, as well as monitoring side effects and safety.
The study also analyzed Trop-2 protein levels in tumor samples to see if higher levels were linked to better treatment outcomes. Researchers found no strong connection between Trop-2 expression and response to SG. The treatment was generally well tolerated, though some patients experienced serious side effects.
These findings suggest that SG could be a potential treatment option for patients with advanced EC who have already tried other therapies.
How Can I Apply This Information?
This research highlights a new possible treatment for patients with advanced endometrial cancer who have few remaining options after chemotherapy and immunotherapy. However, this was a phase II study, meaning more research is needed to confirm the effectiveness of SG before it can become a standard treatment.
If you or a loved one has advanced endometrial cancer, talk to a doctor about emerging treatments and clinical trials that may be available. Healthcare providers may also consider SG as a potential option for further investigation in patients who have exhausted standard treatments.
A larger phase III clinical trial is planned to further evaluate SG in endometrial cancer, which could help determine its role in future cancer care.
Source:
Santin AD, Corr BR, Spira A, Willmott L, Butrynski J, Tse KY, Patel J, Mekan S, Wu T, Lin KW, Kuo P. Efficacy and safety of sacituzumab govitecan in patients with advanced solid Tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer. Journal of Clinical Oncology. 2024 Oct 10;42(29):3421-9. https://pubmed.ncbi.nlm.nih.gov/39083724/
